Experienced in Ascites

Ken Kato

Chiba, JP 
Experienced in Ascites
Chiba, JP 
OverviewLocationsClinical Research

Overview

Ken Kato practices in Chiba, Japan. Mr. Kato is rated as an Experienced expert by MediFind in the treatment of Ascites. His top areas of expertise are Esophageal Cancer, Gastroesophageal Junction Cancer, Stomach Cancer, Endoscopy, and Tissue Biopsy.

His clinical research consists of co-authoring 449 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Ascites.

Gender
Male

Locations

Chiba, 2600856, Japan
Other Locations
Chuo, Japan
Department Of Head And Neck, Tokyo, Japan
Kurume, Japan
Chuo, 2608670, Japan
Sapporo, Japan
Department Of Head And Neck, Chuo, Japan
Tsukiji, 1040045, Japan
Sayama, Japan
Saitama, Japan
Kawahara, 6068507, Japan
Japan
Kawagoe, 3501165, Japan
Nagoya, Japan
Showa, Japan
Toyoake, Japan
Sumiyoshi, 5588585, Japan
Kyoto, 1040045, Japan
Sayo, 6795148, Japan
Toyooka, Japan
Yushima, 1138519, Japan
Nakamichi, 5378511, Japan
Okazaki, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug, Biological
Study Drugs: Cisplatin, Capecitabine, Paclitaxel, Fluorouracil (5-FU), Oxaliplatin, Tislelizumab
Study Phase: Phase 3

449 Total Publications

Study protocol of a randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for advanced or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU).
Study protocol of a randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for advanced or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU).
Journal: BMC cancer
Published: September 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kato's expertise for a condition
ConditionClose
View All 46 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile